tradingkey.logo

Entrada Therapeutics Inc <TRDA.OQ> expected to post a loss of 79 cents a share - Earnings Preview

ReutersMay 5, 2025 1:14 PM
  • Entrada Therapeutics Inc TRDA.OQ TRDA.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The Boston Massachusetts-based company is expected to report a 82.8% decrease in revenue to $10.171 million from $59.12 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Entrada Therapeutics Inc is for a loss of 79 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Entrada Therapeutics Inc is $23.00​, above​ its last closing price of $9.23. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.67

-0.67

0.03

Beat

104.5

Sep. 30 2024

-0.71

-0.73

-0.35

Beat

51.9

Jun. 30 2024

0.14

0.15

1.55

Beat

969​

Mar. 31 2024

-0.61

-0.59

0.68

Beat

214.5

​​Dec. 31 2023

0.12

-0.17

-0.29

Missed

-72.6

Sep. 30 2023

-0.76

-0.74

1.02

Beat

238.6​

Jun. 30 2023

-0.68

-0.69

-0.78

Missed

-13

Mar. 31 2023

0.90

0.97

-0.21

Missed

-121.7

This summary was machine generated May 5 at 13:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI